Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Study Identifies Novel Chemicals Targeting Cancer Stem Cells

Published: Wednesday, November 28, 2012
Last Updated: Wednesday, November 28, 2012
Bookmark and Share
Verastem, Inc., announced that researchers have published a study utilizing the cancer stem cell screening assay exclusively licensed to Verastem to identify novel chemicals that preferentially kill cancer stem cells.

Published in the Journal of Biomolecular Screening, researchers at the Broad Institute of Harvard University and the Massachusetts Institute of Technology utilized the screen originally developed in the laboratories of Verastem scientific cofounders Robert Weinberg, Ph.D. and Eric Lander, Ph.D. Due to the difficulty in propagating cancer stem cells outside of the tumor environment, the researchers created unique cancer stem cell-like cells and used phenotypic high-throughput screening to evaluate 300,718 compounds for their ability to preferentially kill cancer stem cells. The screen identified 2,244 hits and further characterized selective compounds.

“This study demonstrates the power of the cancer stem cell screening technology that was developed by our founders and underpins our research at Verastem,” said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research. “To date, innovation in cancer therapy has been limited by a myopic focus only on targeting bulk tumor cells with little regard for resistant cancer stem cell populations. Verastem is harnessing the power of cancer stem cell-directed screens to identify novel drugs that have the ability to kill the cellular components of the tumor that resist current therapies and drive tumor recurrence.”

The top three chemical series described in the current study are exclusively licensed to Verastem and are part of a portfolio of drugs being advanced for the treatment of a broad range of cancer indications.
Verastem has built a pipeline of novel chemical series that have demonstrated the unique ability to kill cancer stem cells and plans to enter into multiple clinical studies, including a potential registration study in mesothelioma, over the next 12 months.

The article is titled “Phenotypic High-Throughput Screening Elucidates Target Pathway in Breast Cancer Stem-Like Cells.” View the complete text of the study at http://bit.ly/WfDzSB


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Verastem Discloses Research Results and Updated Clinical Plans
Company hosted its annual Research and Development Day where Robert Weinberg, Ph.D., Verastem co-founder and chair of the Scientific Advisory Board, gave a seminar on cancer stem cells.
Thursday, July 12, 2012
Scientific News
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!